Stay updated on Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page revision label updated from v3.6.4 to v3.6.5, reflecting a new iteration of the page metadata. This change does not modify the study content or visible details.
    Difference
    0.1%
    Check dated 2026-08-08T20:47:10.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.3 to v3.6.4. This reflects a small update to the page version rather than changes to substantive study information.
    Difference
    0.1%
    Check dated 2026-07-25T13:05:45.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    A new publication citation has been added to the Publications section, detailing updated subgroup analyses of JBCRG-M06/EMERALD for HER2-positive locally advanced or metastatic breast cancer and listing authors such as Masuda et al. The citation is for Breast Cancer Research and Treatment (2026) with DOI 10.1007/s10549-026-08004-5.
    Difference
    0.1%
    Check dated 2026-07-11T05:57:22.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.2 to v3.6.3, indicating a small update to the page’s metadata. No substantive content changes are introduced.
    Difference
    0.1%
    Check dated 2026-07-03T23:58:57.000Z thumbnail image
  8. Check
    64 days ago
    Change Detected
    Summary
    - The page's revision tag changed from v3.6.0 to v3.6.2, indicating a backend/template update. No study data or visible content was altered.
    Difference
    0.1%
    Check dated 2026-06-26T23:18:49.000Z thumbnail image
  9. Check
    78 days ago
    Change Detected
    Summary
    The page now states that recruitment has ended, and new guidance sections are added for reading the study record and joining the study, along with a standardized Intervention/Treatment heading and a new revision tag.
    Difference
    0.4%
    Check dated 2026-06-12T16:34:26.000Z thumbnail image

Stay in the know with updates to Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page.